CL2020000973A1 - Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes. - Google Patents

Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes.

Info

Publication number
CL2020000973A1
CL2020000973A1 CL2020000973A CL2020000973A CL2020000973A1 CL 2020000973 A1 CL2020000973 A1 CL 2020000973A1 CL 2020000973 A CL2020000973 A CL 2020000973A CL 2020000973 A CL2020000973 A CL 2020000973A CL 2020000973 A1 CL2020000973 A1 CL 2020000973A1
Authority
CL
Chile
Prior art keywords
procedures
compositions
treatment
cell lymphoma
diffuse large
Prior art date
Application number
CL2020000973A
Other languages
English (en)
Spanish (es)
Inventor
Zachary ZIMMERMAN
Xiaohong Alicia Zhang
Peter Christopher Holland
Janet Franklin
Gregory Friberg
Original Assignee
Merck Sharp & Dohme
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Amgen Inc filed Critical Merck Sharp & Dohme
Publication of CL2020000973A1 publication Critical patent/CL2020000973A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CL2020000973A 2017-10-13 2020-04-09 Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes. CL2020000973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762571870P 2017-10-13 2017-10-13

Publications (1)

Publication Number Publication Date
CL2020000973A1 true CL2020000973A1 (es) 2020-12-28

Family

ID=64110107

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000973A CL2020000973A1 (es) 2017-10-13 2020-04-09 Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes.

Country Status (15)

Country Link
US (1) US20200262919A1 (cg-RX-API-DMAC7.html)
EP (1) EP3694520A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020536923A (cg-RX-API-DMAC7.html)
KR (1) KR20200068655A (cg-RX-API-DMAC7.html)
CN (1) CN111212646A (cg-RX-API-DMAC7.html)
AU (1) AU2018347457A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007203A2 (cg-RX-API-DMAC7.html)
CA (1) CA3075291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000973A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090565A1 (cg-RX-API-DMAC7.html)
IL (1) IL273805A (cg-RX-API-DMAC7.html)
MX (2) MX2020003395A (cg-RX-API-DMAC7.html)
SG (1) SG11202002374RA (cg-RX-API-DMAC7.html)
TW (1) TW201922283A (cg-RX-API-DMAC7.html)
WO (1) WO2019075366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
TW202200615A (zh) * 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses
WO2024097218A1 (en) * 2022-11-01 2024-05-10 TeneoTwo, Inc. Methods of treating non-hodgkin lymphoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
EP3302501B1 (en) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
KR20180023968A (ko) * 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법

Also Published As

Publication number Publication date
CN111212646A (zh) 2020-05-29
CA3075291A1 (en) 2019-04-18
JP2024001071A (ja) 2024-01-09
KR20200068655A (ko) 2020-06-15
MX2024001888A (es) 2024-02-29
TW201922283A (zh) 2019-06-16
BR112020007203A2 (pt) 2020-10-20
EP3694520A1 (en) 2020-08-19
MX2020003395A (es) 2020-08-03
JP2020536923A (ja) 2020-12-17
SG11202002374RA (en) 2020-04-29
EA202090565A1 (ru) 2020-10-13
WO2019075366A1 (en) 2019-04-18
AU2018347457A1 (en) 2020-04-09
US20200262919A1 (en) 2020-08-20
IL273805A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
LT3661514T (lt) Mavakamtenas, skirtas naudoti gydant hipertrofinę kardiomiopatiją
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
IL256056A (en) Ezh2 inhibitors for treating lymphoma
PT3407888T (pt) Compostos de piridopirroloquinoxalina, suas composições e utilizações
PL3658140T3 (pl) Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
LT3426226T (lt) Oftalmologinė kompozicija
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej
EP3617287A4 (en) THICKENING AGENT, COMPOSITION AND SHEET
HUE043259T2 (hu) Sarzskeverõ üzemeltetési eljárása, valamint sarzskeverõ az eljárás foganatosítására
EP3415518A4 (en) MACROCYCLUS AND COMPOSITION THEREOF
GB2588261B (en) Apparatus, use of the apparatus and arrangement
IL267172A (en) Compositions containing methylphenidate prodrugs, processes for their preparation and use
EP3654982A4 (en) 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
EP3555127C0 (en) AGENTS, USES AND METHODS
EP3597225A4 (en) TREATMENT PROCESS
EP3517581A4 (en) COATING COMPOSITION, COATING FILM, AND COATING PROCESS
DK3302478T3 (da) Pac-1 kombinations behandling
EP3536718A4 (en) FLUORINATED POLYMER AND COMPOSITION OF SURFACE TREATMENT AGENT
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
LT3273957T (lt) Biotinas, skirtas demielinizuojančių neuropatijų gydymui
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.